Menu
RegimensEvidenceLearnHealthTrainingQualityAboutFAQ
Take the quizES

Everstack Evidence

CLast reviewed

Berberine and glucose metabolism

Multiple meta-analyses of randomized trials show a metabolic signal, but most trials were small, short, and of generally low methodological quality.

Published Sources checked 6 sourcesEverstack research teamHow we work

Editorial section. Research summaries are not product claims and contain no product links or offers. A summary is never proof that any product works.

The question
What do controlled human studies and meta-analyses show about berberine and markers of glucose and lipid metabolism?
Study design
Two meta-analyses of randomized trials (Dong 2012: 14 trials, 1,068 participants; Lan 2015: 27 trials, 2,569 patients), a cell and rodent AMPK study (Lee 2006), a small clinical trial in adults with elevated glucose (Yin 2008), and a human CYP inhibition study (Guo 2012). [1][2][3][4][5][6]
What they found
Across the pooled trials, berberine plus lifestyle change lowered fasting glucose and improved lipid markers more than lifestyle alone, with no clear advantage over standard oral glucose-lowering drugs in Lan 2015. In lab models, berberine activated AMPK and increased glucose transporter movement in muscle cells. In healthy men, two weeks at 300 mg three times a day inhibited CYP2D6, CYP2C9 and CYP3A4, so it can change blood levels of many medicines. [1][2][3][4][5][6]
Limitations
Most trials were small, short, and conducted in China, with generally low methodological quality. Surrogate metabolic markers are not the same as hard clinical outcomes. Drug-interaction risk is real.
What this does not mean
Berberine is not a substitute for prescribed care. It is a candidate SKU, not for sale. If we offer it, the only claim will be structure/function: supports healthy glucose metabolism. NIH's NCCIH notes that goldenseal (a berberine-containing herb) may affect glucose control in people taking metformin, and that people who are pregnant or breastfeeding should not use it.
Sources
  1. Dong H et al. Evid Based Complement Alternat Med. 2012;2012:591654. doi.org/10.1155/2012/591654
  2. Lan J et al. J Ethnopharmacol. 2015;161:69-81. doi.org/10.1016/j.jep.2014.09.049
  3. Lee YS et al. Diabetes. 2006;55(8):2256-2264. doi.org/10.2337/db06-0006
  4. Yin J et al. Metabolism. 2008;57(5):712-717. doi.org/10.1016/j.metabol.2008.01.013
  5. Guo Y et al. Eur J Clin Pharmacol. 2012;68(2):213-217. doi.org/10.1007/s00228-011-1108-2
  6. NCCIH: Goldenseal. www.nccih.nih.gov/health/goldenseal

Spot an error? Email hello@everstackhealth.com and we will correct it within 48 hours.